Dr. Mattias Ivarsson is an experienced biotech entrepreneur who studied biomedical engineering and obtained a PhD in pharmaceutical sciences at ETH Zurich in Switzerland. In parallel to his studies, he gained professional experience through work at McKinsey & Company, Siemens Management Consulting and the World Health Organization. He founded Inositec Inc. in 2015 as a postdoc during his Pioneer Fellowship at ETH Zurich, where he co-invented and developed Inositec’s proprietary chemical series during his tenure in the laboratory of drug formulation and delivery of Prof. Jean-Christophe Leroux. Dr. Ivarsson won extensive recognition for his business idea, including nomination to the Forbes 30 under 30 list. Inositec was acquired by Vifor Pharma (Now CSL Vifor) in 2021 with the lead asset entering Phase 1 testing. Dr. Ivarsson is now entrepreneur-in-residence at BiomedVC, a Swiss biotech venture capital fund, and founding CEO and board member of Salvina Therapeutics Inc.